Phase 4
N=86
TAP Block Catheters vs Liposomal Bupivacaine for Pain Control After Colorectal Surgery
Colorectal Surgery · TAP Blocks
Bottom Line
View on ClinicalTrials.gov: NCT03080142 ↗Enrolled (actual)
86
Serious AEs
0.0%
Results posted
Apr 2021
Primary outcome: Primary: Mean Opioid Consumption in Morphine Opioid Equivalents in mg — 112.12; 97.95 IV morphine equivalents (mg)
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Exparel (Drug); Ropivacaine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, Davis
- Primary completion
- May 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Opioid Consumption in Morphine Opioid Equivalents in mg |
112.12; 97.95 | — |
Summary
This is a prospective randomized study designed to compare the pain control from a single shot of liposomal bupivacaine (Exparel) against transversus abominus plane (TAP) catheters with ropivicaine bolus in patients undergoing elective colorectal surgery.
Eligibility Criteria
Inclusion Criteria
- Patients scheduled for elective colorectal surgery with Dr. Linda Farkas
Exclusion Criteria
- Patients under 18 years of age
- Patient over 90 years of age
- Pregnancy
- Prisoners
- Patients unable to provide consent
- Patients on systemic anticoagulation therapy
- Patients with an allergy to local anesthetics
Data sourced from ClinicalTrials.gov (NCT03080142). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.